Technical Analysis for CERS - Cerus Corporation

Grade Last Price % Change Price Change
grade B 5.68 0.53% 0.03
CERS closed up 0.53 percent on Friday, January 18, 2019, on 59 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Flat
See historical CERS trend table...

Date Alert Name Type % Chg
Jan 18 Stochastic Sell Signal Bearish 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Narrow Range Bar Range Contraction 0.53%
Jan 17 NR7 Range Contraction 0.53%
Jan 17 NR7-2 Range Contraction 0.53%
Jan 17 Overbought Stochastic Strength 0.53%
Jan 16 Shooting Star Candlestick Bearish 0.18%
Jan 16 Lizard Bearish Bearish Day Trade Setup 0.18%
Jan 16 NR7 Range Contraction 0.18%
Jan 16 NR7-2 Range Contraction 0.18%

Older signals for CERS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Cerus Corporation, together with its subsidiary, Cerus Europe B.V., operates as a biomedical products company that focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company's INTERCEPT Blood System is based on its proprietary technology for controlling biological replication and is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria, and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. Its INTERCEPT Blood System for platelets is designed to inactivate blood-borne pathogens in platelets donated for transfusion; and INTERCEPT Blood System for plasma is designed to inactivate blood-borne pathogens in plasma donated for transfusion. The company is also developing INTERCEPT Blood System for red blood cells, which is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets its platelet and plasma systems through its direct sales force and distributors primarily in Europe, the Commonwealth of Independent States, and the Middle East. The company has collaboration agreements with Baxter International, Inc. for the development and commercialization of the INTERCEPT Blood System. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Is CERS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 8.05
52 Week Low 3.77
Average Volume 888,678
200-Day Moving Average 6.3627
50-Day Moving Average 5.403
20-Day Moving Average 5.3605
10-Day Moving Average 5.657
Average True Range 0.2227
ADX 17.84
+DI 22.7675
-DI 16.965
Chandelier Exit (Long, 3 ATRs ) 5.1219
Chandelier Exit (Short, 3 ATRs ) 5.3731
Upper Bollinger Band 6.0014
Lower Bollinger Band 4.7196
Percent B (%b) 0.75
BandWidth 23.911949
MACD Line 0.0767
MACD Signal Line 0.031
MACD Histogram 0.0457
Fundamentals Value
Market Cap 619.89 Million
Num Shares 109 Million
EPS -0.61
Price-to-Earnings (P/E) Ratio -9.31
Price-to-Sales 8.39
Price-to-Book 7.86
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.88
Resistance 3 (R3) 5.88 5.82 5.84
Resistance 2 (R2) 5.82 5.77 5.82 5.83
Resistance 1 (R1) 5.75 5.74 5.79 5.75 5.82
Pivot Point 5.69 5.69 5.71 5.69 5.69
Support 1 (S1) 5.62 5.64 5.66 5.62 5.54
Support 2 (S2) 5.56 5.61 5.56 5.53
Support 3 (S3) 5.49 5.56 5.52
Support 4 (S4) 5.49